Recap: TELA Bio Q4 Earnings
Portfolio Pulse from Benzinga Insights
TELA Bio (NASDAQ:TELA) reported Q4 earnings with an EPS of $-0.53, missing estimates by -23.0% against an expected $-0.43. Revenue increased by $5.38 million from the same period last year. Despite beating EPS estimates in Q3 2023, the share price dropped by 19.0% the following day. The company's past earnings performance shows a mixed trend of beating and missing EPS estimates.
March 21, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TELA Bio reported a Q4 EPS of $-0.53, missing estimates by -23.0%, with a revenue increase of $5.38 million YoY. The company has a history of mixed earnings performance.
The missed earnings estimate by -23.0% is likely to negatively impact investor sentiment in the short term, especially considering the company's history of mixed earnings performance. The previous quarter's beat on EPS followed by a 19.0% drop in share price the next day suggests that even positive earnings surprises have not consistently led to positive stock price movements. This pattern may lead investors to react negatively to the Q4 earnings miss.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100